Abstract
Breast cancer is one of the most prevalent cancers in women. Chemoresistance is a major obstacle for the treatment of breast cancer. We investigated the role of long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) in paclitaxel (PTX) resistance in breast cancer. CASC2 expression was increased in PTX-resistant clinical samples and cell lines. PTX induced CASC2 expression in a concentration-dependent manner. Downregulation of CASC2 increased PTX toxicity and decreased IC50 value, while upregulation of CASC2 decreased PTX toxicity and increased IC50 value in MCF-7/PTX and MDA-MB-231/PTX cells. Moreover, downregulation of CASC2 decreased tumor growth in xenograft mice implanted with MCF-7/PTX cells. miR-18a-5p possessed a putative binding site in 3′-UTR of CASC2 and cyclin-dependent kinase 19 (CDK19). In PTX-resistant breast cancer cells, miR-18a-5p expression was decreased. CASC2 and miR-18a-5p could negatively regulate the expression of each other. CDK19 expression could be negatively regulated by miR-18a-5p, but positively regulated by CASC2. miR-18a-5p mimics or downregulation of CDK19 decreased tumor growth in xenograft mice implanted with MCF-7/PTX cells. In summary, we identified that CASC2 activated PTX resistance in breast cancer through regulation of miR-18a-5p/CDK19. We highlight the importance of CASC2/miR-18a-5p/CDK19 axis in the chemoresistance of breast cancer and provide potential targets for the improving chemotherapy of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiyama M, Sowa Y, Taniguchi T, Watanabe M, Yogosawa S, Kitawaki J, Sakai T (2017) Three combined treatments, a novel HDAC inhibitor OBP-801/YM753, 5-fluorouracil, and paclitaxel, induce G(2) phase arrest through the p38 pathway in human ovarian cancer cells. Oncol Res 25(8):1245–1252. https://doi.org/10.3727/096504017x14850164661097
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Pina V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403):405–409. https://doi.org/10.1038/nature11154
Caetano-Pinto P, Jansen J, Assaraf YG, Masereeuw R (2017) The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. Drug Resist Updat 30:15–27. https://doi.org/10.1016/j.drup.2017.01.002
Chen W, Zheng R, Zuo T, Zeng H, Zhang S, He J (2016) National cancer incidence and mortality in China, 2012. Chin J Cancer Res 28(1):1–11. https://doi.org/10.3978/j.issn.1000-9604.2016.02.08
Cherdyntseva NV, Litviakov NV, Denisov EV, Gervas PA, Cherdyntsev ES (2017) Circulating tumor cells in breast cancer: functional heterogeneity, pathogenetic and clinical aspects. Exp Oncol 39(1):2–11
Fan JC, Zeng F, Le YG, Xin L (2018) LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR-24-3p. J Cell Biochem 119(8):6391–6397. https://doi.org/10.1002/jcb.26479
Fatica A, Bozzoni I (2014) Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 15(1):7–21. https://doi.org/10.1038/nrg3606
Gao Z, Wang H, Li H, Li M, Wang J, Zhang W, Liang X, Su D, Tang J (2018) Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway. Int J Oncol 53(5):2081–2090. https://doi.org/10.3892/ijo.2018.4522
Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21(11):1253–1261. https://doi.org/10.1038/nm.3981
Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, Perera RJ (2011) The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 71(11):3852–3862. https://doi.org/10.1158/0008-5472.Can-10-4460
Li X, Zhang Z, Li Y, Zhao Y, Zhai W, Yang L, Kong D, Wu C, Chen Z, Teng CB (2017) miR-18a counteracts AKT and ERK activation to inhibit the proliferation of pancreatic progenitor cells. Sci Rep 7:45002. https://doi.org/10.1038/srep45002
Li W, Li Z, Wei L, Zheng A (2018a) Evaluation of paclitaxel nanocrystals in vitro and in vivo. Drug Res 68(4):205–212. https://doi.org/10.1055/s-0043-119461
Li Y, Liang Y, Sang Y, Song X, Zhang H, Liu Y, Jiang L, Yang Q (2018b) MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis 9(1):14. https://doi.org/10.1038/s41419-017-0030-7
Malhotra A, Jain M, Prakash H, Vasquez KM, Jain A (2017) The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer. Oncotarget 8(66):110671–110684. https://doi.org/10.18632/oncotarget.22577
O’Sullivan CC, Loprinzi CL, Haddad TC (2018) Updates in the evaluation and management of breast cancer. Mayo Clin Proc 93(6):794–807. https://doi.org/10.1016/j.mayocp.2018.03.025
Panayotopoulou EG, Muller AK, Borries M, Busch H, Hu G, Lev S (2017) Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. Oncotarget 8(28):45088–45104. https://doi.org/10.18632/oncotarget.15125
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093
Renganathan L, Ramasubramaniam S, Al-Touby S, Seshan V, Al-Balushi A, Al-Amri W, Al-Nasseri Y, Al-Rawahi Y (2014) What do omani women know about breast cancer symptoms? Oman Med J 29(6):408–413. https://doi.org/10.5001/omj.2014.110
Schettini F, Giuliano M, De Placido S, Arpino G (2016) Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives. Cancer Treat Rev 50:129–141. https://doi.org/10.1016/j.ctrv.2016.09.004
Schmitt AM, Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29(4):452–463. https://doi.org/10.1016/j.ccell.2016.03.010
Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang E, Shao L, Li A, Yang N, Han X, Pan B, Zhang Z, Sun L, Sun Y (2016) LncRNA H19 confers chemoresistance in ERalpha-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget 7(49):81452–81462. https://doi.org/10.18632/oncotarget.13263
Wang KC, Chang HY (2011) Molecular mechanisms of long noncoding RNAs. Mol Cell 43(6):904–914. https://doi.org/10.1016/j.molcel.2011.08.018
Wang R, Zhang T, Yang Z, Jiang C, Seng J (2018a) Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med 22(9):4068–4075. https://doi.org/10.1111/jcmm.13679
Wang Z, Wang X, Zhou H, Dan X, Jiang L, Wu Y (2018b) Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma. Acta Biochim Biophys Sin 50(3):263–272. https://doi.org/10.1093/abbs/gmx148
Xue Z, Zhu X, Teng Y (2018) Long noncoding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer. Mol Med Rep. https://doi.org/10.3892/mmr.2018.9550
Yang L, Froberg JE, Lee JT (2014a) Long noncoding RNAs: fresh perspectives into the RNA world. Trends Biochem Sci 39(1):35–43. https://doi.org/10.1016/j.tibs.2013.10.002
Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich W, Roland BC, Khashab M, Singh VK, Shin EJ, Yang X, Verma AK, Meltzer SJ, Mori Y (2014b) Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut 63(6):881–890. https://doi.org/10.1136/gutjnl-2013-305266
Zhang N, Zhang H, Liu Y, Su P, Zhang J, Wang X, Sun M, Chen B, Zhao W, Wang L, Wang H, Moran MS, Haffty BG, Yang Q (2018a) SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death Differ. https://doi.org/10.1038/s41418-018-0158-8
Zhang S, Leng T, Zhang Q, Zhao Q, Nie X, Yang L (2018b) Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3 K/AKT/mTOR pathway. Biomed Pharmacother 102:302–308. https://doi.org/10.1016/j.biopha.2018.03.071
Zhang Y, Zhu M, Sun Y, Li W, Wang Y, Yu W (2018c) Up-regulation of lncRNA CASC2 suppresses cell proliferation and metastasis of breast cancer via inactivating of the TGF-ss signaling pathway. Oncology Res. https://doi.org/10.3727/096504018x15199531937158
Zhao L, Zhang Y, Zhang Y (2018) Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-kappaB axis. J Cell Physiol 233(10):6661–6670. https://doi.org/10.1002/jcp.26446
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zheng, P., Dong, L., Zhang, B. et al. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19. Histochem Cell Biol 152, 281–291 (2019). https://doi.org/10.1007/s00418-019-01794-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00418-019-01794-4